Johnson & Johnson Says FDA Grants Priority Review To Subcutaneous Amivantamab For Recurrent Or Metastatic Head And Neck Cancer, Citing 42% Overall Response Rate In OrigAMI-4 Study
Share
Why It Matters
Johnson & Johnson's new cancer medicine got fast-track approval from health officials because it helped 42% of patients with serious head and neck cancer. When a company gets this kind of speed-up, it shows their medicine might work well, which investors watch as a sign the company could grow.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.